Search Results - "López Vega, J M"

Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte-colony stimulating factor to the TAC regimen by Martín, M., Lluch, A., Seguí, M. A., Ruiz, A., Ramos, M., Adrover, E., Rodríguez-Lescure, Á., Grosse, R., Calvo, L., Fernandez-Chacón, C., Roset, M., Antón, A., Isla, D., del Prado, P. Martínez, Iglesias, L., Zaluski, J., Arcusa, A., López-Vega, J. M., Muñoz, M., Mel, J. R.

“…Background: The aim of the study was to analyse the toxicity and health related quality of life (HRQoL) of breast cancer patients treated with FAC…”
Get full text

Epirubicin–cyclophosphamide adjuvant chemotherapy plus tamoxifen administered concurrently versus sequentially: randomized phase III trial in postmenopausal node-positive breast cancer patients. A GEICAM 9401 study by Pico, C., Martin, M., Jara, C., Barnadas, A., Pelegri, A., Balil, A., Camps, C., Frau, A., Rodriguez-Lescure, A., Lopez-Vega, J. M., de la Haba, J., Tres, A., Alvarez, I., Alba, E., Arcusa, A., Oltra, A., Batista, N., Checa, T., Perez-Carrion, R., Curto, J.

“…Background: A prospective randomized clinical trial was implemented to assess whether the concomitant or the sequential addition of tamoxifen to chemotherapy…”
Get full text

The natural course of emesis after carboplatin treatment by Martin, M, Diaz-Rubio, E, Sánchez, A, Almenarez, J, López-Vega, J M

“…Twenty-eight patients receiving their first cycle of carboplatin treatment (300-400 mg/m2) entered a prospective study in which the natural course and…”
Get more information

Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with weekly high-dose 48-hour continuous-infusion fluorouracil for advanced colorectal cancer: A Spanish Cooperative Group for Gastrointestinal Tumor Therapy (TTD) study by Aranda, E., Díaz-Rubio, E., Cervantes, A., Antón-Torres, A., Carrato, A., Massutí, T., Tabernero, J. M., Sastre, J., Trés, A., Aparicio, J., López-Vega, J. M., Barneto, I., García-Conde, J.

“…Purpose The objective of this multicenter study was to compare the efficacy and toxicity profiles of a combination of 5-fluorouracil (5-FU) given by bolus…”
Get full text

A definition for aggressive disease in patients with HER-2 negative metastatic breast cancer: an expert consensus of the Spanish Society of Medical Oncology (SEOM) by González, A., Lluch, A., Aba, E., Albanell, J., Antón, A., Álvarez, I., Ayala, F., Barnadas, A., Calvo, L., Ciruelos, E., Cortés, J., de la Haba, J., López-Vega, J. M., Martínez, E., Muñoz, M., Peláez, I., Redondo, A., Rodríguez, Á., Rodríguez, C. A., Ruíz, A., Llombart, A.

“…Purpose To converge on an expert opinion to define aggressive disease in patients with HER2-negative mBC using a modified Delphi methodology. Methods A panel…”
Get full text

Carboplatin: an active drug in metastatic breast cancer by Martín, M, Díaz-Rubio, E, Casado, A, Santabárbara, P, López Vega, J M, Adrover, E, Lenaz, L

“…The study was undertaken to assess the antitumor activity of carboplatin 400 mg/m2 intravenously every 4 weeks in metastatic breast cancer (MBC). Thirty-four…”
Get more information

Sequential doxorubicin and docetaxel as first-line treatment in metastatic breast cancer: a GEICAM-9801 phase II study by ALBA, E, RIBELLES, N, ANTON, A, PEREZ-CARRION, R, LOPEZ-VEGA, J. M, LLANOS, M, PELEGRI, A, FLORIAN, J, MENENDEZ, M, GODES, M. J

“…To evaluate the efficacy and the toxicity profile of the sequential administration of doxorubicin and docetaxel as first-line chemotherapy in metastatic breast…”
Get full text

Resistance to chemotherapy via Stat3-dependent overexpression of Bcl-2 in metastatic breast cancer cells by REAL, Pedro J, SIERRA, Angels, DE JUAN, Ana, SEGOVIA, Jose C, LOPEZ-VEGA, Jose M, FERNANDEZ-LUNA, Jose L

“…Disruption of apoptosis may allow metastatic cell survival and confer resistance to chemotherapeutic drugs. We have analysed the molecular pathways that…”
Get full text

Abstract P5-16-11: Residual cancer burden (RCB) as a strong prognosis factor in breast cáncer (BC) patients treated with neoadjuvant chemotherapy (NACT) based on carboplatin, doxorubicin and taxanes by de Juan Ferré, A, Mayorga Fernández, M, Alonso Bartolomé, P, Azcarretazabal González-Ontaneda, T, Muñoz Cacho, P, Múgica Estébanez, M, Anchuelo Latorre, J, Mata Velasco, E, Saíz Isa, L, López Vega, JM

“…Purpose: Many pathologic response systems have been used since the arrival of NACT. The RCB is a standardized method, but not universally implemented (Symanns…”
Get full text

Motor neuron disease in Cantabria by López-Vega, J M, Calleja, J, Combarros, O, Polo, J M, Berciano, J

“…Sixty-two patients with motor neuron disease (MND), encompassing amyotrophic lateral sclerosis (ALS), progressive bulbar palsy (PBP) and progressive muscular…”
Get more information

Ifosfamide in advanced epidermoid head and neck cancer by MARTIN, M, DIAZ-RUBIO, E, GONZALEZ LARRIBA, J. L, CASADO, A, SASTRE, J, LOPEZ-VEGA, J. M, ALMENAREZ, J, DOMINGUEZ, S

“…A total of 37 men with epidermoid head and neck cancer whose disease had recurred following primary treatment (surgery and/or radiotherapy) received first-line…”
Get full text

Phase III Trial of Adjuvant Capecitabine After Standard Neo-/Adjuvant Chemotherapy in Patients With Early Triple-Negative Breast Cancer (GEICAM/2003-11_CIBOMA/2004-01) by Lluch, Ana, Barrios, Carlos H, Torrecillas, Laura, Ruiz-Borrego, Manuel, Bines, Jose, Segalla, Jose, Guerrero-Zotano, Ángel, García-Sáenz, Jose A, Torres, Roberto, de la Haba, Juan, García-Martínez, Elena, Gómez, Henry L, Llombart, Antonio, Bofill, Javier Salvador, Baena-Cañada, José M, Barnadas, Agustí, Calvo, Lourdes, Pérez-Michel, Laura, Ramos, Manuel, Fernández, Isaura, Rodríguez-Lescure, Álvaro, Cárdenas, Jesús, Vinholes, Jeferson, Martínez de Dueñas, Eduardo, Godes, Maria J, Seguí, Miguel A, Antón, Antonio, López-Álvarez, Pilar, Moncayo, Jorge, Amorim, Gilberto, Villar, Esther, Reyes, Salvador, Sampaio, Carlos, Cardemil, Bernardita, Escudero, Maria J, Bezares, Susana, Carrasco, Eva, Martín, Miguel

“…Operable triple-negative breast cancers (TNBCs) have a higher risk of relapse than non-TNBCs with standard therapy. The GEICAM/2003-11_CIBOMA/2004-01 trial…”
Get full text

Abstract P2-16-10: Safety of pertuzumab plus trastuzumab plus vinorelbine for first-line treatment of patients with HER2-positive locally advanced or metastatic breast cancer by Perez, EA, López-Vega, JM, Del Mastro, L, Petit, T, Zamagni, C, Freudensprung, U, Bastière-Truchot, L, Walker, R, Andersson, M

“…Background: HER2 overexpression or amplification, occuring in ∼15-20% of breast cancers (BC), is associated with a poor prognosis. Trastuzumab (T) and…”
Get full text

Phase II study of docetaxel (T), carboplatin (C), and gemcitabine (G), in advanced tumors of unknown primary site by Mel Sr, J. R., Provencio, M., Balañá, C., López-Vega, J. M., Casado, A., Segura, A., Cervera, J. M., Martí, J. L., Munárriz, J., Arranz, F.

“…Abstract only 12028 Background: Treatment of tumors of unknown primary site is still a challenge nowadays. D, C and G have shown high activity in solid tumors…”
Get full text

Biweekly gemcitabine, doxorubicin and paclitaxel (GAT) regimen as neoadjuvant chemotherapy (NC) in locally advanced breast cancer (LABC) patients: Final results from 2002–01 GEICAM study by Sánchez-Rovira, P., Antón, A., Margelí, M., Velasco, A., Lomas, M., Crespo, C., López-Vega, J. M., Casado, J., Carrasco, E.

“…Abstract only…”
Get full text

Intravenous and oral magnesium supplementations in the prophylaxis of cisplatin-induced hypomagnesemia. Results of a controlled trial by Martin, M, Diaz-Rubio, E, Casado, A, López Vega, J M, Sastre, J, Almenarez, J

“…The effects of oral and intravenous magnesium supplementation on cisplatin (CDDP)-induced hypomagnesemia were investigated in 41 patients treated with 100…”
Get more information

A multicenter randomized phase II trial of granulocyte‐colony stimulating factor‐supported, platinum‐based chemotherapy with flexible midcycle cisplatin administration in patients with advanced ovarian carcinoma by Hidalgo, Manuel, Mendiola, César, López‐Vega, José Manuel, Castellano, Daniel, Mendez, Miguel, Batiste‐Alenton, Eduardo, López‐Brea, Marta, Belon, Joaquín, Batista, Jose N., Cortés‐Funes, Hernán

“…BACKGROUND The purpose of this study was to analyze whether the addition of granulocyte‐colony stimulating factor (G‐CSF) to platinum‐based combination…”
Get full text

Phase I study of mitonafide with a 3-day administration schedule : early interruption due to severe central nervous system toxicity by DIAZ-RUBIO, E, MARTIN, M, LOPEZ-VEGA, J. M, CASADO, A, BENAVIDES, A

“…Eleven patients with solid tumors for whom effective therapy was not available entered a phase I study of mitonafide given as a short intravenous (i.v.)…”
Get full text

RELOAD extension for data discovery and transfer in data-centric publish–subscribe environments by Lopez-Vega, Jose M., Camarillo, Gonzalo, Povedano-Molina, Javier, Lopez-Soler, Juan M.

“…Data-Centric Publish–Subscribe (DCPS) is an architectural and communication paradigm where applications exchange data-content through a common data-space using…”
Get full text

A multicenter randomized Phase II trial of granulocyte-colony stimulating factor-supported, platinum-based chemotherapy with flexible midcycle cisplatin administration in patients with advanced ovarian carcinoma. PSAMOMA Cooperative Group, Spain by Hidalgo, M, Mendiola, C, López-Vega, J M, Castellano, D, Mendez, M, Batiste-Alenton, E, López-Brea, M, Belon, J, Batista, J N, Cortés-Funes, H

“…The purpose of this study was to analyze whether the addition of granulocyte-colony stimulating factor (G-CSF) to platinum-based combination chemotherapy could…”
Get full text